KEYMED BIO-B (02162.HK): Non-Executive Director Dr. Wang Minchuan Resigns, Effective 4 September 2026
NewTimeSpace News: On 6 September 2026, Keymed Biosciences Inc. (stock code: 02162) announced that Dr. Wang Minchuan has tendered his resignation as a non-executive director, effective 4 September 2026, in order to devote more time to other business activities.
Dr. Wang confirmed that he has no disagreement with the Board, has made no claim against the company in connection with his resignation, and there are no other matters relating to his resignation that need to be brought to the attention of shareholders or the Stock Exchange. The Board expressed gratitude for his contribution during his term of office.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- KEYMED BIO-B (02162.HK): Exclusive License Agreement for Stapokibart Covering 18 Countries and Regions Including Southeast Asia and Central Asia
- KEYMED BIO-B(02162.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.22 billion, turned profitable from a loss YoY
- KEYMED BIO-B (02162.HK): Proposes RMB Share Issuance and STAR Market Listing on Shanghai Stock Exchange, Subject to Shareholder and Regulatory Approvals
- KEYMED BIO-B (02162.HK): Phase II trial of CM512 (TSLP x IL-13 bispecific antibody) for chronic rhinosinusitis with nasal polyps meets all study endpoints; Phase III to advance with 300mg once-half-yearly regimen
- KEYMED BIO-B (02162.HK): Global Phase III Trial of CMG901 (AZD0901) Meets Primary Endpoint, Delivers Improved OS for 2L+ Gastric Cancer; AstraZeneca Forecasts Peak Sales of USD3-5 Billion
